ATE327331T1 - Rekombinante antikörper zur humanen therapie - Google Patents

Rekombinante antikörper zur humanen therapie

Info

Publication number
ATE327331T1
ATE327331T1 AT02012106T AT02012106T ATE327331T1 AT E327331 T1 ATE327331 T1 AT E327331T1 AT 02012106 T AT02012106 T AT 02012106T AT 02012106 T AT02012106 T AT 02012106T AT E327331 T1 ATE327331 T1 AT E327331T1
Authority
AT
Austria
Prior art keywords
recombinant antibodies
human therapy
therapy
human
recombinant
Prior art date
Application number
AT02012106T
Other languages
English (en)
Inventor
Roland A Newman
Nabil Hanna
Ronald W Raab
Original Assignee
Biogen Idec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27112830&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE327331(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogen Idec Inc filed Critical Biogen Idec Inc
Application granted granted Critical
Publication of ATE327331T1 publication Critical patent/ATE327331T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2821—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against ICAM molecules, e.g. CD50, CD54, CD102
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT02012106T 1991-07-25 1992-07-24 Rekombinante antikörper zur humanen therapie ATE327331T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73506491A 1991-07-25 1991-07-25
US85628192A 1992-03-23 1992-03-23

Publications (1)

Publication Number Publication Date
ATE327331T1 true ATE327331T1 (de) 2006-06-15

Family

ID=27112830

Family Applications (2)

Application Number Title Priority Date Filing Date
AT02012106T ATE327331T1 (de) 1991-07-25 1992-07-24 Rekombinante antikörper zur humanen therapie
AT92917108T ATE237638T1 (de) 1991-07-25 1992-07-24 Rekombinante antikörper zur humanen therapie

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT92917108T ATE237638T1 (de) 1991-07-25 1992-07-24 Rekombinante antikörper zur humanen therapie

Country Status (24)

Country Link
EP (3) EP1715045A3 (de)
JP (1) JP3048640B2 (de)
KR (1) KR0137806B1 (de)
AP (1) AP307A (de)
AT (2) ATE327331T1 (de)
AU (1) AU673499B2 (de)
BG (1) BG62656B1 (de)
BR (1) BR9206313A (de)
CA (1) CA2114015C (de)
CZ (1) CZ289472B6 (de)
DE (2) DE69233011T2 (de)
DK (2) DK0605442T3 (de)
ES (2) ES2265005T3 (de)
FI (1) FI117703B (de)
HU (2) HUT70272A (de)
IL (1) IL102640A0 (de)
MY (1) MY121185A (de)
NO (1) NO318097B1 (de)
NZ (1) NZ243706A (de)
OA (1) OA09879A (de)
PT (1) PT100735B (de)
RO (1) RO116404B1 (de)
SK (2) SK285046B6 (de)
WO (1) WO1993002108A1 (de)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2064915C (en) 1989-08-07 2001-05-29 Deborah A. Rathjen Tumour necrosis factor binding ligands
US20030225254A1 (en) 1989-08-07 2003-12-04 Rathjen Deborah Ann Tumour necrosis factor binding ligands
GB9022545D0 (en) 1990-10-17 1990-11-28 Wellcome Found Culture medium
US5919452A (en) * 1991-03-18 1999-07-06 New York University Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US7192584B2 (en) 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
WO1993002190A1 (en) * 1991-07-15 1993-02-04 The Wellcome Foundation Limited Production of antibodies
US6136310A (en) 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
US7744877B2 (en) 1992-11-13 2010-06-29 Biogen Idec Inc. Expression and use of anti-CD20 Antibodies
EP1005870B1 (de) 1992-11-13 2009-01-21 Biogen Idec Inc. Therapeutische Verwendung von chimerischen und markierten Antikörpern, die gegen ein Differenzierungs-Antigen gerichtet sind, dessen Expression auf menschliche B Lymphozyten beschränkt ist, für die Behandlung von B-Zell-Lymphoma
ATE157100T1 (de) 1993-06-03 1997-09-15 Therapeutic Antibodies Inc Antikoerperfragmente in therapie
US5429746A (en) 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
ATE195428T1 (de) * 1994-04-26 2000-09-15 Kanebo Ltd Arznei für rheumatoide arthritis
ATE198895T1 (de) * 1994-10-25 2001-02-15 Glaxo Group Ltd Verwendung von bindungsreagenzien gegen cd23 in der behandlung von autoimmunkrankheiten
CZ172497A3 (en) * 1994-12-07 1997-10-15 Hoffmann La Roche Fragments of monoclonal substance exhibiting immunosuppressor activity
US6113898A (en) 1995-06-07 2000-09-05 Idec Pharmaceuticals Corporation Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
US7175847B1 (en) 1995-06-07 2007-02-13 Biogen Idec Inc. Treating intestinal inflammation with anti-CD80 antibodies that do not inhibit CD80 binding to CTLA-4
US7153508B2 (en) 1995-06-07 2006-12-26 Biogen Idec Inc. Treatment of B cell lymphoma using anti-CD80 antibodies that do not inhibit the binding of CD80 to CTLA-4
GB9624038D0 (en) * 1996-11-19 1997-01-08 Sandoz Ltd Organic compounds
US7033589B1 (en) 1997-02-20 2006-04-25 Biogen Idec Ma Inc. γ-1 anti-human CD23 monoclonal antibodies and use thereof as therapeutics
US6011138A (en) * 1997-02-20 2000-01-04 Idec Pharmaceuticals Corporation Gamma-1 anti-human CD23 monoclonal antibodies
US6893636B2 (en) * 1997-02-20 2005-05-17 Biogen Idec Ma Inc. Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeutics
JP2002512776A (ja) * 1998-04-28 2002-05-08 スミスクライン・ビーチャム・コーポレイション 免疫原性の低下したモノクローナル抗体
GB9809839D0 (en) * 1998-05-09 1998-07-08 Glaxo Group Ltd Antibody
HK1041221A1 (zh) 1998-08-11 2002-07-05 Idec药物公司 包括施用抗-cd20抗体的b-细胞淋巴瘤联合疗法
EP2289543A1 (de) 1998-11-09 2011-03-02 Biogen Idec Inc. Verwendung vom chimären anti-CD20 Antikörper zur Behandlung von mit zirkulierenden Krebszellen verbundenen hematologischen bosärtigen Krebs
AU777970C (en) 1999-05-07 2006-08-17 F. Hoffman-La Roche Ag Treatment of autoimmune diseases with antagonists which bind to B cell surface markers
US8557244B1 (en) 1999-08-11 2013-10-15 Biogen Idec Inc. Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody
EP1297168A2 (de) * 2000-07-03 2003-04-02 Gala Design, Inc. Expressionsvektoren
EP2151493B1 (de) * 2000-07-03 2012-06-13 Catalent Pharma Solutions, LLC Wirtzellen mit mehreren integrierenden Vektoren
US6852510B2 (en) 2000-07-03 2005-02-08 Gala Design Inc Host cells containing multiple integrating vectors
UA81743C2 (uk) 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
US20050101012A1 (en) 2001-03-12 2005-05-12 Gerold Schuler CD4+CD25+ regulatory T cells from human blood
EP1241249A1 (de) * 2001-03-12 2002-09-18 Gerold Schuler Regulatorische CD4+CD25+ T Zellen aus menschlichem Blut
TWI334439B (en) 2001-08-01 2010-12-11 Centocor Inc Anti-tnf antibodies, compositions, methods and uses
US7384738B2 (en) 2002-03-28 2008-06-10 Bremel Robert D Retrovirus-based genomic screening
US20040038304A1 (en) 2002-03-28 2004-02-26 Gala Design, Inc. Antibody libraries
US8222033B2 (en) 2002-08-12 2012-07-17 Argos Therapeutics, Inc. CD4+CD25− T cells and Tr1-like regulatory T cells
ES2744275T3 (es) 2002-10-17 2020-02-24 Genmab As Anticuerpos monoclonales humanos contra CD20 para su uso en el tratamiento de esclerosis múltiple
EP1692174A2 (de) * 2003-11-07 2006-08-23 Amgen Inc. Affen-immunoglobulinsequenzen
WO2005048935A2 (en) 2003-11-14 2005-06-02 Brigham And Women's Hospital, Inc. Methods of modulating immunity
SI1730191T1 (sl) 2004-03-30 2011-11-30 Glaxo Group Ltd Imunoglobulin-vezavni hOSM
JP5848861B2 (ja) 2004-04-20 2016-01-27 ジェンマブ エー／エスＧｅｎｍａｂ Ａ／Ｓ Ｃｄ２０に対するヒトモノクローナル抗体
TWI307630B (en) 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins
WO2007117264A2 (en) * 2005-08-03 2007-10-18 Fraunhofer Usa, Inc. Compositions and methods for production of immunoglobulins
CA2619245A1 (en) * 2005-08-15 2007-02-22 Arana Therapeutics Limited Chimeric antibodies with new world primate regions
EP1945668A4 (de) * 2005-08-15 2009-07-22 Arana Therapeutics Ltd Synthetische antikörper mit framework-regionen von neuweltprimaten
JP2009519983A (ja) * 2005-12-20 2009-05-21 アラーナ・テラピューティクス・リミテッド 部分的な新世界ザル結合領域を有するキメラ抗体
US7846439B2 (en) 2006-02-01 2010-12-07 Cephalon Australia Pty Ltd Domain antibody construct
EP2526959B1 (de) 2006-08-11 2017-08-02 CSL Limited Behandlung von lungenerkrankungszuständen
TW200817438A (en) 2006-08-17 2008-04-16 Hoffmann La Roche A conjugate of an antibody against CCR5 and an antifusogenic peptide
US8323653B2 (en) 2006-09-08 2012-12-04 Medimmune, Llc Humanized anti-CD19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
AU2007319604B2 (en) 2006-10-19 2011-03-24 Csl Limited High affinity antibody antagonists of interleukin-13 receptor alpha 1
EP2068922B1 (de) 2006-10-19 2012-06-27 CSL Limited Anti-il-13r-alpha-1-antikörper und ihre verwendung
TW200902544A (en) 2007-03-13 2009-01-16 Hoffmann La Roche Peptide-complement conjugates
US20090022720A1 (en) 2007-07-20 2009-01-22 Stephan Fischer Conjugate of an antibody against CD4 and antifusogenic peptides
CN102159250B (zh) 2008-08-11 2014-08-06 尼克塔治疗公司 多臂的聚合烷酸酯偶联物
US8415291B2 (en) 2008-10-31 2013-04-09 Centocor Ortho Biotech Inc. Anti-TNF alpha fibronectin type III domain based scaffold compositions, methods and uses
GB2476681B (en) 2010-01-04 2012-04-04 Argen X Bv Humanized camelid VH, VK and VL immunoglobulin domains
DK2646470T3 (en) 2010-11-30 2017-05-08 Hoffmann La Roche ANTI-TRANSFERRIN RECEPTOR ANTIBODIES WITH LOW AFFINITY AND ITS USE FOR TRANSPORTING THERAPEUTIC SCFV OVER THE BLOOD-BRAIN BARRIER
US20130331443A1 (en) 2010-12-22 2013-12-12 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of taxane-based compounds
US10894087B2 (en) 2010-12-22 2021-01-19 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds
US20140088021A1 (en) 2011-05-27 2014-03-27 Nektar Therapeutics Water-Soluble Polymer-Linked Binding Moiety and Drug Compounds
DE202012013147U1 (de) * 2011-10-31 2015-01-22 Jan-Niklas Keltsch Einhändig bedienbare Verpackung
EP3328429B1 (de) 2015-07-31 2025-07-16 The Research Institute at Nationwide Children's Hospital Peptide und antikörper zur beseitigung von biofilmen
WO2017066719A2 (en) 2015-10-14 2017-04-20 Research Institute At Nationwide Children's Hospital Hu specific interfering agents
US10465003B2 (en) 2016-02-05 2019-11-05 Janssen Biotech, Inc. Anti-TNF antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes
WO2018129078A1 (en) 2017-01-04 2018-07-12 Research Institute At Nationwide Children's Hospital Dnabii vaccines and antibodies with enhanced activity
AU2018206560B9 (en) 2017-01-04 2025-04-03 Research Institute At Nationwide Children's Hospital Antibody fragments for the treatment of biofilm-related disorders
AU2017396503B2 (en) 2017-01-30 2025-02-06 Janssen Biotech, Inc. Anti-TNF antibodies, compositions, and methods for the treatment of active Psoriatic arthritis
CN110418652A (zh) 2017-02-07 2019-11-05 詹森生物科技公司 用于治疗活动性强直性脊柱炎的抗tnf抗体、组合物和方法
EP3595445B1 (de) 2017-03-15 2024-09-04 The Research Institute at Nationwide Children's Hospital Zusammensetzung und verfahren zur brechung bakterieller biofilme ohne begleitentzündung
CN111683969A (zh) 2018-01-10 2020-09-18 生物发明国际公司 抗体的新型组合和用途
JP7541513B2 (ja) 2018-10-05 2024-08-28 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル 細菌バイオフィルムの酵素的破壊のための組成物および方法
CN113874073A (zh) 2019-05-23 2021-12-31 詹森生物科技公司 用针对IL-23和TNFα的抗体的联合疗法治疗炎性肠病的方法
KR20220032066A (ko) 2019-07-08 2022-03-15 더 리서치 인스티튜트 앳 네이션와이드 칠드런스 하스피탈 생물막을 파괴하기 위한 항체 조성물
CN115768466A (zh) 2020-05-21 2023-03-07 詹森生物科技公司 用抗IL-23和TNFα抗体的联合疗法治疗炎性肠病的方法
US20230322933A1 (en) 2020-06-04 2023-10-12 Bioinvent International Ab Model for prediction of tolerability issues in connection with intravenous administration of therapeutic antibodies
WO2022189508A1 (en) 2021-03-09 2022-09-15 Bioinvent International Ab Novel combinations of antibodies and uses thereof
WO2023161448A1 (en) * 2022-02-24 2023-08-31 Abnomx Bv Human-like target-binding proteins
TW202336033A (zh) 2022-03-07 2023-09-16 瑞典商生物創新國際有限公司 抗體之新穎組合及用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993002190A1 (en) * 1991-07-15 1993-02-04 The Wellcome Foundation Limited Production of antibodies

Also Published As

Publication number Publication date
JPH06509708A (ja) 1994-11-02
BR9206313A (pt) 1995-04-11
SK285046B6 (sk) 2006-05-04
OA09879A (en) 1994-09-15
PT100735B (pt) 1999-07-30
DE69233011T2 (de) 2003-11-06
DK0605442T3 (da) 2003-08-04
EP0605442B1 (de) 2003-04-16
AP9200413A0 (en) 1992-07-31
EP0605442A1 (de) 1994-07-13
EP1266965A3 (de) 2003-01-02
AU673499B2 (en) 1996-11-14
CA2114015C (en) 2002-12-10
HU211881A9 (en) 1995-12-28
BG62656B1 (bg) 2000-04-28
AU2425592A (en) 1993-02-23
EP1266965B1 (de) 2006-05-24
SK285960B6 (sk) 2007-12-06
BG98411A (bg) 1995-02-28
JP3048640B2 (ja) 2000-06-05
FI940336A0 (fi) 1994-01-24
NZ243706A (en) 1994-08-26
DK1266965T3 (da) 2006-09-25
EP1266965A2 (de) 2002-12-18
NO940219L (no) 1994-03-25
CA2114015A1 (en) 1993-02-04
HUT70272A (en) 1995-09-28
WO1993002108A1 (en) 1993-02-04
DE69233628T2 (de) 2007-04-26
NO940219D0 (no) 1994-01-21
DE69233628D1 (de) 2006-06-29
IL102640A0 (en) 1993-01-14
MY121185A (en) 2006-01-28
CZ14994A3 (en) 1994-07-13
NO318097B1 (no) 2005-01-31
EP1715045A3 (de) 2006-12-13
ATE237638T1 (de) 2003-05-15
AP307A (en) 1994-01-31
DE69233011D1 (de) 2003-05-22
EP0605442A4 (de) 1995-07-12
FI940336L (fi) 1994-03-10
FI117703B (fi) 2007-01-31
ES2265005T3 (es) 2007-02-01
ES2196002T3 (es) 2003-12-16
PT100735A (pt) 1993-10-29
EP1715045A2 (de) 2006-10-25
SK8894A3 (en) 1994-09-07
HU9400201D0 (en) 1994-05-30
KR0137806B1 (ko) 1998-04-30
RO116404B1 (ro) 2001-01-30
CZ289472B6 (cs) 2002-01-16

Similar Documents

Publication Publication Date Title
ATE237638T1 (de) Rekombinante antikörper zur humanen therapie
NO980915D0 (no) Rekombinante anti-CD4-antistoff egnet for human terapi
FI922785A7 (fi) Terapeuttisia valmisteita
FI920737A7 (fi) Terapeuttisia peptidejä
FI934964L (fi) Teraupetiskt aemne
FI923379L (fi) Terapeutiska amider
FI884924A7 (fi) Yhdistelmä-DNA-tekniikalla tuotettuja ihmisimmunoglobuliineja
NO924395D0 (no) Rekombinante menneske-faktor viii derivater
ITTO920014V0 (it) Dispositivo di copertura per arto artificiale
GB9221654D0 (en) Recombinant human anti-cytomegalovirus antibodies
DK64592D0 (da) Peptider til terapeutisk behandling
FI934189A7 (fi) Transdermalt terapeutiskt plaoster
FI924744L (fi) Terapeutiska aemnen
FI923759L (fi) Terapeutiska bensazapinfoereningar
FI890175A7 (fi) Ihmisen yhdistelmä-interleukiini-1-a-polypeptidejä
ZA925615B (en) Recombinant antibodies for human therapy
EP0540575A4 (en) Human meg-csf protein and methods
FI920701L (fi) Anordning foer terapeutisk tryckbehandling
DK149591D0 (da) Proteinpraeparat
DE69434900D1 (de) Menschliche chemokin-polypeptide
EP0463571A3 (en) Recombinant human osteocalcin
DK147891D0 (da) Proteinpraeparat
IE883256L (en) Human immunoglobulins by recombinant dna techniques
MD279B1 (ro) Metoda de terapie tisulara
ITPD910230A0 (it) Nuovi anticorpi monoclonali specifici per il fattore neurofonico ciliare (cntf) umano ricombinante

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1266965

Country of ref document: EP